According to statistics from the World Health Organization (WHO), lung cancer ranks Mexico 11th worldwide in terms of incidence.
Faced with the health challenges this disease represents, an Argentine company called Biomarkers comes to Mexico with technological innovation in biomarkers.
These allow patients and their treating physicians to know the DNA of a tumor within 72 hours to make precision medicine decisions more efficient and thus extend each person’s life expectancy.
The Biomakers company is a leader in precision medicine in Latin America specializing in genetic and molecular oncology testing.
How do biomarkers work?
Biomarkers or genetic and molecular tests are innovative parameters that allow the identification of mutated cancer genes.
At the same time they allow the classification of the tumor and the stage in which it is found; Along with the above, the relevant individual treatment is prescribed.
The company uses Next Generation Sequencing (NGS) technology for this process.
In addition, it simultaneously analyzes various molecular changes that allow the doctor to provide oncological treatment.
These range from existing treatments to clinical trials in which patients may be candidates.
“We test patients via biopsy to collect tumor DNA, providing results obtained in record time,” says Ruben Salanova, medical director and co-founder of Biomakers.
Experts point out that this advance in medicine allows patients to increase their life expectancy by up to five years.
Lung cancer has a high mortality rate and biomarkers improve the quality and survival of these patients. It was developed by Dr., a doctor in the Department of Thoracic Oncology, National Cancer Institute (INCan). As explained by Maritza Ramos.
He adds that the use of biomarkers could reduce the cost of care and complications of toxicity from treatments such as chemotherapy.
The treatment can process up to 10,000 genes at the same time and detect cancer mutations.
According to AMIIF, cancer is the third cause of death in Mexico, specifically lung cancer representing 5.3% of all cases of neoplasms in the country.
It is estimated that by 2030, there will be approximately 135,000 deaths from lung cancer, which is 50% more than today.
Biotechnology within reach of doctors and patients
Since its inception in 2014, Biomaker develops and implements technical projects.
What stands out is its Single Platform for Oncological Testing (PLUTÓN), which has emerged to make time between healthcare professionals and patients more efficient.
This is achieved thanks to the fact that the doctor can request tests in an agile, practical and free way to centralize all the information and generate statistics.
The biomakers have the Advanced Tumor Biobank and the largest set of Big Data on cancer in LATAM.
It has 70,000 samples of tumors and their biomarkers for the discovery and development of new drugs.
The biomakers have operations in Argentina, Mexico and Brazil from where it also conducts trials on patients from other countries such as Chile, Uruguay, Paraguay, Ecuador, Peru, Panama, Costa Rica and Colombia.